Renal cell carcinoma (RCC) is linked to signature molecular alterations that influence their morphological characteristics and associated clinicopathologic features. This has been fueled by an incremental understanding of the molecular underpinnings of RCC. The current 2022 WHO classification has now incorporated novel diagnostic entities as well as a new category of “ molecularly defined renal carcinomas ”. This review delves into our current understanding of molecular correlates with the evolving taxonomic classification of RCC. This review’s contents consist of molecularly defined entities with morphological annotations that correspond to distinct morphologies such as clear cell, papillary, and eosinophilic. Thus, we highlight the morphological context, diagnostic algorithm, and the available biomarkers that can assist practicing pathologists in these respective categories and thereby correctly diagnosing these unique tumor entities. Wherever possible a brief summary of the current therapeutics that align with morphological and molecular correlates have been providedas well.
Humble et al. (Wed,) studied this question.